Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Altimmune Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ALT
Nasdaq
2834
https://altimmune.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Altimmune Inc
Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High?
- May 23rd, 2022 1:55 pm
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
- May 20th, 2022 11:30 am
Altimmune to Present at Upcoming Investor Conferences
- May 16th, 2022 11:30 am
Altimmune (NASDAQ:ALT) surges 19% this week, taking three-year gains to 111%
- May 14th, 2022 1:51 pm
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
- May 12th, 2022 11:00 am
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
- May 5th, 2022 11:30 am
What Kind Of Investors Own Most Of Altimmune, Inc. (NASDAQ:ALT)?
- Apr 1st, 2022 7:40 pm
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
- Apr 1st, 2022 11:00 am
The Biotech Sector Nears an Inflection Point; Analysts Offer 3 Stocks to Consider
- Mar 22nd, 2022 4:47 pm
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
- Mar 15th, 2022 11:01 am
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
- Mar 8th, 2022 12:00 pm
Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for
- Feb 17th, 2022 8:02 pm
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
- Jan 31st, 2022 12:00 pm
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
- Jan 28th, 2022 9:36 am
It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits.
- Jan 24th, 2022 7:48 pm
Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022
- Jan 3rd, 2022 12:00 pm
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec 13th, 2021 11:00 am
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer
- Dec 13th, 2021 11:00 am
Altimmune to Present at Upcoming Investor and Scientific Conferences
- Nov 22nd, 2021 9:01 pm
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
- Nov 9th, 2021 9:01 pm
Scroll